ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

dupilumab

Also written as “Dupilumab”, “Dupilumab SAR231893” and “Dupilumab (SAR231893)”.

Its studies are mostly in Dermatitis, Atopic · Asthma · Eosinophilic Esophagitis · Nasal Polyps · Pulmonary Disease, Chronic Obstructive, led by 3 companies.

Drug pageDupilumab: every studyAll 180 studies of it, academic ones too, with its approvals, label and forms.
Furthest: phase 4, since Jul 16, 201993 company-led studies, 14 open or runningNext primary completion: Feb 7, 2027 (phase 4)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Sanofi529 open or runningphase 4since Jul 16, 2019Mar 9, 2011Feb 7, 2027phase 4 · NCT07905547
Regeneron Pharmaceuticalsits history only404 open or runningphase 4since Dec 17, 2019Nov 10, 2009Apr 24, 2027phase 4 · NCT06572228
Andover Eye Associatesits history only11 open or runningphase 2since Mar 2, 2020Mar 2, 2020none ahead

Also a collaborator on its studies: Aimmune Therapeutics and Statistics & Data.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of Sanofi only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

Before these, 35 studies since Mar 9, 2011.

  1. Aug 31, 2022Phase 3 study in Chronic UrticariaNCT05526521 · 15 enrolled · United States, Canada, Japan
  2. Nov 13, 2022Phase 4 study in Dermatitis, AtopicNCT05624112 · 44 enrolled · China
  3. Dec 26, 2022Phase 4 study in Dermatitis, AtopicNCT05680298 · 34 enrolled · China
  4. Feb 3, 2023Phase 2 study in Colitis, UlcerativeNCT05731128 · 68 enrolled · United States, Argentina, Canada and more
  5. May 18, 2023Phase 3 study in Chronic Rhinosinusitis With Nasal PolypsNCT05878093 · 63 enrolled · China
  6. Jul 28, 20233 phase 1 studiesNCT05976386, NCT05976373, NCT05976360
  7. Aug 1, 2023Phase 4 study in Dermatitis, AtopicNCT05983068 · 48 enrolled · United States, United Kingdom
  8. Oct 19, 2023Phase 4 study in Eosinophilic EsophagitisNCT06101095 · 69 enrolled · United States, Brazil, Canada and more
  9. Dec 19, 2023Phase 3 study in Respiratory SoundsNCT06191315 · 90 planned · United States, Argentina, Brazil and more
  10. Feb 27, 2024Phase 3 study in Prurigo NodularisNCT06293053 · 18 planned · United States
  11. Nov 12, 20242 phase 3 studies in NeurodermatitisNCT06687980, NCT06687967
  12. Jun 27, 2025Phase 4 study in Pulmonary Disease, Chronic ObstructiveNCT07053423 · 218 planned · United States, Argentina, Austria and more
  13. Jun 8, 2026Phase 1 study in Healthy VolunteersNCT07646548 · 40 enrolled · United States
  14. Oct 23, 2026Phase 4 study in Dermatitis, AtopicNCT07905547 · 56 planned

Ahead

  1. Feb 7, 2027Primary completion: phase 4 study in Dermatitis, AtopicNCT07905547
  2. Mar 16, 2027Primary completion: phase 4 study in AsthmaNCT05097287
  3. Apr 29, 2027Primary completion: phase 4 study in Dermatitis, AtopicNCT05983068
  4. Jun 2, 2027Primary completion: phase 3 study in PruritusNCT05263206

TargetBeta

IL4R →read by rule
“Interleukin-4 receptor subunit alpha antagonist”ChEMBL 37, by rule

Other programs on IL4R

ProgramCompanyFurthest phaseStudies
drotokibartJiangsu HengRui Medicinephase 38
TQH2722Sino Biopharmaceuticalphase 37
SHR-1819Jiangsu HengRui Medicinephase 35

Studies

All 52 Sanofi leads, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07905547Dermatitis, Atopic4Not yet recruitingFeb 7, 202756
NCT07646548Healthy Volunteers · United States1CompletedSep 30, 202640
NCT07053423Pulmonary Disease, Chronic Obstructive · United States, Argentina, Austria and more4RecruitingDec 23, 2028218
NCT06687980Neurodermatitis · United States, Argentina, Belgium and more3CompletedJun 8, 2026138
NCT06687967Neurodermatitis · United States, Argentina, Canada and more3CompletedJun 8, 2026142
NCT06293053Prurigo Nodularis · United States3RecruitingOct 28, 202718
NCT06191315Respiratory Sounds · United States, Argentina, Brazil and more3By invitationDec 21, 202890
NCT06101095Eosinophilic Esophagitis · United States, Brazil, Canada and more4Active, not recruitingNov 5, 202569
NCT05983068Dermatitis, Atopic · United States, United Kingdom4Active, not recruitingApr 29, 202748
NCT05976386Healthy Volunteers · United States1CompletedSep 24, 2021182
NCT05976373Healthy Volunteers · United States1CompletedMar 30, 201538
NCT05976360Healthy Volunteer · United States1CompletedJan 17, 201538
NCT05878093Chronic Rhinosinusitis With Nasal Polyps · China3CompletedSep 6, 202463
NCT05731128Colitis, Ulcerative · United States, Argentina, Canada and more2Active, not recruitingMay 13, 202668
NCT05680298Dermatitis, Atopic · China4CompletedDec 22, 202334
NCT05624112Dermatitis, Atopic · China4CompletedJan 25, 202444
NCT05526521Chronic Urticaria · United States, Canada, Japan3CompletedNov 11, 202415
NCT05263206Pruritus · United States, Argentina, Canada and more3RecruitingJun 2, 2027284
NCT05097287Asthma · United States, Belgium, Brazil and more4Active, not recruitingMar 16, 20271,339
NCT05049122Chronic Rhinosinusitis With Nasal Polyps · Japan4CompletedDec 21, 202225
NCT04998604Asthma · United States, Belgium, Canada and more4CompletedOct 16, 2024360
NCT04823130Dermatitis, Atopic · United States, Germany4CompletedJun 30, 202254
NCT04718870Dermatitis, Atopic · United States, United Kingdom4CompletedSep 7, 202241
NCT04684524Allergic Fungal Sinusitis · United States, Argentina, Canada and more3CompletedDec 14, 202462
NCT04681729Cold Urticaria · United States, Argentina, Canada and more3CompletedFeb 2, 202382
NCT04678882Dermatitis, Atopic · Japan3CompletedDec 14, 202162
NCT04678856Sinusitis · United States, Argentina, Belgium and more2CompletedNov 14, 202371
NCT04502862Asthma · United States, Argentina, Canada and more4CompletedOct 3, 2023202
NCT04456673Pulmonary Disease, Chronic Obstructive · United States, Argentina, Australia and more3CompletedFeb 28, 2024935
NCT04447417Dermatitis, Atopic · United States, Canada4CompletedJun 17, 202152
NCT04400318Asthma · United States, Bulgaria, Denmark and more4CompletedJun 26, 2023109
NCT04202679Neurodermatitis · United States, Canada, Chile and more3CompletedAug 30, 2021160
NCT04183335Neurodermatitis · United States, Argentina, China and more3CompletedNov 12, 2021151
NCT04180488Chronic Urticaria · United States, Argentina, Canada and more3CompletedAug 1, 2024397
NCT04033367Dermatitis, Atopic · United States, Australia, France and more4CompletedOct 6, 2021188
NCT03930732Pulmonary Disease, Chronic Obstructive · United States, Argentina, Bulgaria and more3CompletedFeb 8, 2023939
NCT03912259Dermatitis, Atopic · China3CompletedFeb 14, 2020165
NCT03782532Asthma · China, India3CompletedMay 21, 2022486
NCT03620747Asthma · United States, Argentina, Belgium and more3CompletedFeb 18, 2022393
NCT03560466Asthma · United States, Argentina, Australia and more3CompletedApr 1, 2025378
NCT02948959Asthma · United States, Argentina, Australia and more3CompletedAug 26, 2020408
NCT02912468Nasal Polyps · United States, Bulgaria, Czechia and more3CompletedJul 5, 2018276
NCT02898454Chronic Rhinosinusitis Phenotype With Nasal Polyps (CRSwNP) · United States, Argentina, Australia and more3CompletedAug 27, 2018448
NCT02573233Asthma · United States, Canada, Denmark and more2CompletedJan 3, 201842
NCT02528214Asthma · United States, Argentina, Belgium and more3CompletedSep 20, 2017210
NCT02414854Asthma · United States, Argentina, Australia and more3CompletedJul 29, 20171,902
NCT02134028Asthma · United States, Argentina, Australia and more3CompletedOct 11, 20192,282
NCT01920893Nasal Polyps · United States, Belgium, Spain and more2CompletedNov 201460
NCT01854047Asthma · United States, Argentina, Australia and more2CompletedNov 2014776
NCT01537653Healthy · Japan1CompletedOct 201232
NCT01537640Healthy · United States1CompletedJul 201230
NCT01312961Asthma · United States2CompletedOct 2012104

How it is read

Names in the registry

  • “Dupilumab”, 55 entries
  • “Dupilumab SAR231893”, 13 entries
  • “dupilumab”, 10 entries
  • “Dupilumab (SAR231893)”, 5 entries
  • “REGN668”, 4 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.